

REVIEW ARTICLE

DRUG THERAPY

Alastair J.J. Wood, M.D., *Editor*

Drug-Induced Prolongation of the QT Interval

Dan M. Roden, M.D.

IN THE PAST DECADE, THE SINGLE MOST COMMON CAUSE OF THE WITHDRAWAL or restriction of the use of drugs that have already been marketed has been the prolongation of the QT interval associated with polymorphic ventricular tachycardia, or torsade de pointes (Fig. 1), which can be fatal.¹ Nine structurally unrelated drugs that were marketed in the United States or elsewhere for a range of noncardiovascular indications have been removed from the market or had their availability severely restricted because of this rare form of toxicity. These drugs are terfenadine, astemizole, grepafloxacin, terodiline, droperidol, lidoflazine, sertindole, levomethadyl, and cisapride.

A convergence of data obtained from clinicians, basic electrophysiologists, and geneticists who have studied the congenital long-QT syndrome (also characterized by torsade de pointes) has resulted in some understanding of the mechanisms whereby drugs may cause this type of arrhythmia. Guidelines,^{2,3} which are still evolving, are aimed at predicting whether a new drug carries this risk. Paradoxically, however, increased knowledge has also illuminated the fact that the current predictors of this serious side effect are imperfect, both for individual patients and for populations of patients who are exposed to a given drug. Thus, although clinicians, members of regulatory bodies, and drug developers may be able to predict that a given drug may carry some risk, they can neither assess nor quantify it accurately. In this article, I summarize the current knowledge about molecular and clinical predictors of drug-induced prolongation of the QT interval and torsade de pointes, consider how new molecular predictors of a drug's activity might be incorporated into drug-development programs and clinical practice, and suggest a general approach to drugs that are suspected of causing this problem.


THE CLINICAL BACKGROUND OF LONG-QT SYNDROME

Syncope associated with the initiation of quinidine therapy has been recognized since the 1920s, and the availability of online electrocardiographic monitoring in the 1960s led to the identification of pause-dependent polymorphic ventricular tachycardia as the underlying mechanism.⁴ The term "torsade de pointes," coined in 1966 to describe the peculiar appearance of a ventricular tachycardia occurring in an elderly woman with heart block,⁵ is often translated as a "twisting of the points," referring to the beat-to-beat changes in the QRS axis (Fig. 1B). Congenital syndromes involving QT-interval prolongation and syncope or sudden death were first described in the late 1950s and early 1960s.⁶⁻⁸ The few electrocardiographically documented cases of syncope or sudden death in patients with a congenital long-QT syndrome have been characterized by torsade de pointes, although the pause dependence that is typical of the drug-related form (Fig. 1) is not always present.⁹

From the Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville. Address reprint requests to Dr. Roden at the Division of Clinical Pharmacology, Vanderbilt University School of Medicine, 532 Medical Research Bldg. 1, Nashville, TN 37232, or at dan.roden@vanderbilt.edu.

N Engl J Med 2004;350:1013-22.

Copyright © 2004 Massachusetts Medical Society.



Although torsade de pointes can occur in many settings (such as heart block, as originally described), it is usually seen in patients with one of the congenital long-QT syndromes or in association with drug therapy. The drugs that are generally considered to confer a risk of torsade de pointes are listed in Table 1. Multiple clinical risk factors (Table 2 and Fig. 1) are often present in an individual case. These factors are not only helpful in estimating the risk for an individual patient but have also provided a starting point for basic research into underlying mechanisms. One example is the elucidation of mechanisms by which hypokalemia increases risk.²³ Another risk factor is female sex, a powerful predictor of the risk of torsade de pointes in patients with congenital²⁴ and acquired¹⁰ long-QT syndromes.²⁵⁻²⁷ How or whether variability in the expression of genes that determine normal cardiac electrophysiology²⁸ explain the sex-dependent risk of torsade de pointes is not yet clear.

A unifying concept, “reduced repolarization reserve,” has been used to explain the variable risk.²⁹

This framework suggests that the physiologic mechanisms that maintain normal cardiac repolarization vary among patients but are not apparent in a basal state. However, exposure to a drug that prolongs the QT interval, or the development of a risk factor such as bradycardia or hypokalemia, is more likely to cause exaggerated QT prolongation in a susceptible patient than in a nonsusceptible one.¹⁸ In vitro studies suggest a corollary — that the risk of torsade de pointes varies even among persons with equivalent degrees of QT prolongation.^{30,31}

PROBLEMS POSED BY TECHNOLOGICAL AND SCIENTIFIC ADVANCES

Clinical observations have been complemented by two major advances in characterizing drug actions in patients — the ability to acquire and analyze huge quantities of electrocardiographic data and the evolving understanding of the molecular and cellular changes that are induced by drugs that produce torsade de pointes. Both developments, how-

ever, have generated new ambiguities with regard to the arrhythmogenic potential of available and newer drugs.

MEASUREMENT AND INTERPRETATION OF THE QT INTERVAL

QT-interval–prolonging antiarrhythmic agents such as sotalol, dofetilide, and ibutilide can prolong the QT interval by more than 50 msec at clinically prescribed doses and may cause torsade de pointes. Indeed, the risk is sufficiently high with these drugs (more than 1 percent^{15,32,33}) that in-hospital cardiac monitoring is recommended when treatment with these agents is initiated.

It is assumed, but has not been proved, that even a small drug-induced increase in the QT interval in a population indicates some risk of torsade de pointes if large numbers of patients are exposed. Indeed, some noncardiovascular drugs that have been withdrawn from the market because they cause torsade de pointes result in a mean increase in the QT interval as small as 5 to 10 msec in populations of patients.^{34,35} Since new drugs have generally been tested in only a few thousand patients at the time of their approval, the fact that no cases of torsade de pointes have been observed before a drug is approved is not very informative; even if no cases are recorded in a data base including 5000 patients, the 95 percent confidence interval for the risk of torsade de pointes would be 0 to 1 in 1600 — with the upper limit reflecting the potential for a very high incidence after marketing. In addition, the arrhythmia itself must be recorded in order to establish the diagnosis firmly, and patients may present not with syncope but with sudden death. If a new drug is being used to treat patients in whom a higher-than-average background incidence of sudden death is anticipated, the diagnosis of drug-induced torsade de pointes may never even be considered. Post-marketing surveillance has helped to identify rare side effects of drugs after they are on the market,^{36,37} but the occurrence of such a fatal arrhythmia, which may be ascribed to an underlying disease, is probably underreported.³⁸

The QT interval is used during drug development and by clinicians as a surrogate marker for the prediction of a serious adverse drug effect, syncope, or death due to torsade de pointes. However, as with many surrogate markers, its relationship to the event of interest is imperfect — the risk of torsade de pointes is not a linear function of the QT interval, nor of the extent of QT-interval prolongation

Table 1. Drugs That May Cause Torsade de Pointes.*

<p>Drugs commonly involved</p> <p>Disopyramide Dofetilide Ibutilide Procainamide Quinidine Sotalol Bepridil</p> <p>Other drugs†</p> <p>Amiodarone Arsenic trioxide Cisapride Calcium-channel blockers: lidoflazine (not marketed in the United States) Antiinfective agents: clarithromycin, erythromycin, halofantrine, pentamidine, sparfloxacin Antiemetic agents: domperidone, droperidol Antipsychotic agents: chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide Methadone</p>

* Further information on the strength of the evidence linking various drugs to torsade de pointes may be found at <http://www.torsades.org>.

† The level of risk associated with these drugs depends on the dose and the population being treated; in general, the risk is probably less than 1 percent.

Table 2. Risk Factors for Drug-Induced Torsade de Pointes.*

<p>Female sex¹⁰ Hypokalemia^{11,12} Bradycardia^{11,12} Recent conversion from atrial fibrillation, especially with a QT-prolonging drug^{13,14} Congestive heart failure¹⁵ Digitalis therapy¹⁶ High drug concentrations (with the exception of quinidine) Rapid rate of intravenous infusion with a QT-prolonging drug¹⁷ Base-line QT prolongation¹⁶ Subclinical long-QT syndrome^{18,19} Ion-channel polymorphisms²⁰⁻²² Severe hypomagnesemia</p>

* Studies providing evidence of the effects are cited in the table.

during drug therapy. Prolongation of the absolute QT interval beyond 500 msec is commonly regarded as conferring an increased risk — a belief that is supported by recent data from a study of patients

with the congenital long-QT syndrome.³⁹ The prolongation of the QT interval to longer than 500 msec during drug therapy should prompt a critical reevaluation of the risks and benefits of that therapy and consideration of therapeutic alternatives, in concert with a search for underlying predisposing factors such as hypokalemia or drug interactions.

Although abnormal QT-interval morphology (Fig. 1A) might predict an increased risk of torsade de pointes, analytic methods for assessing the relationship remain to be validated.⁴⁰ The heart rate is an important variable affecting the QT interval, and a variety of methods have been proposed to derive a "rate-corrected" QT interval that permits the comparison of QT values obtained at different heart rates. Each approach has its deficiencies; no single "correct" method for deriving the QT value has been established.⁴¹ Drugs may independently affect the QT interval and the heart rate, and the successful treatment of a disease (such as infection or psychosis) may itself change the heart rate, further complicating the assessment of the QT interval at varying heart rates.

BASIC ELECTROPHYSIOLOGICAL MECHANISMS


The clinical finding of the lengthening of the QT interval represents the prolongation of action potentials in at least some cells in the ventricular myocardium (Fig. 2). When such prolongation of the action potential is recorded in preparations from animals, it may be followed by the development of deformities of the action potential, termed early after-depolarizations, which can, in turn, generate spontaneous, or "triggered," upstrokes (Fig. 2A). When such an upstroke is propagated through the whole heart, a ventricular ectopic beat preceded by a long QT interval is recorded on the surface electrocardiogram. A number of lines of evidence implicate early after-depolarizations and triggered activity in the genesis of torsade de pointes; notably, the conditions that elicit experimental early after-depolarizations (slow stimulation rates, low extracellular potassium levels, and treatment with QT-interval-prolonging drugs) are those associated with torsade de pointes. Certain populations of cells in the conduction system (Purkinje fibers⁴²) and midmyocardium (M cells⁴⁶) appear to be especially likely to develop early after-depolarizations on drug challenge. Heterogeneity in the development of prolongation of the action potential and early after-depolarizations results in a myocardium that is vul-

nerable to reentrant excitation, the probable proximate cause of torsade de pointes.^{45,47,48}

One promising direction for research into the variability in the risk of torsade de pointes involves defining the molecular mechanisms that control the duration of action potential and the QT interval in the normal heart and in diseases such as the congenital long-QT syndrome or heart failure⁴⁹ (which increase the risk of torsade de pointes). Elegant genetic studies have been invaluable in identifying at least six separate genes that, if mutated, can cause the congenital long-QT syndrome.⁵⁰⁻⁵⁵ Study of one of these genes, the human ether-a-go-go-related gene (*HERG*), which encodes a potassium-channel protein that regulates a major repolarizing potassium current, has been especially informative about drug-associated torsade de pointes. *HERG* controls an important repolarizing current, termed I_{Kr} ; mutations in *HERG* reduce I_{Kr} and thus prolong action potentials in individual cells, causing the congenital long-QT syndrome. In addition, virtually all drugs that prolong the QT interval and cause torsade de pointes also block I_{Kr} .⁵⁶ Unfortunately, this finding is not specific, since many drugs that do not appear to cause torsade de pointes also block this current.

Another important consequence of clinical studies of congenital long-QT syndrome has been the recognition of incomplete penetrance; that is, family members with near-normal QT intervals may nevertheless carry the same mutations in genes associated with long-QT-syndrome disease⁵⁰⁻⁵⁵ that cause QT-interval prolongation and an increased risk of sudden death in their relatives.⁵⁷

Current evidence suggests that 5 to 10 percent of persons in whom torsade de pointes develops on exposure to QT-interval-prolonging drugs harbor mutations associated with the long-QT syndrome and can therefore be viewed as having a subclinical form of the congenital syndrome.^{18,19,58} This clinical observation is entirely consistent with the concept of reduced repolarization reserve arising from a mutation in an ion-channel gene, which predisposes the carrier to drug-induced torsade de pointes. An extension of this concept is that common polymorphisms may cause subtle variations in the function of any gene that contributes to the generation of normal action potentials and that such variation might become apparent only on exposure to an I_{Kr} -blocking drug or other sources of stress (such as hypokalemia or heart failure). The identi-



fication and validation of such variants might have important public health consequences, since such polymorphisms may be frequent (the variants reported to date have frequencies of up to 15 percent), and their frequency may vary among ethnic groups.²⁰⁻²²

IDENTIFICATION OF DRUGS THAT CAUSE TORSADE DE POINTES

The link between torsade de pointes, a clinical drug effect, and changes in molecular and cellular physiology (the blocking of I_{Kr} and the prolongation of the action potential) (Fig. 3) is imperfect. Some drugs (e.g., verapamil and amiodarone) rarely cause torsade de pointes yet do block I_{Kr} .^{59,60} Thus, it is likely that other pharmacologic actions are also involved — actions that prevent torsade de pointes either directly (e.g., by blocking early after-depolar-

izations⁶¹) or indirectly, by blunting the prolongation of the action potential that precedes an arrhythmia. Indeed, amiodarone routinely prolongs the QT interval to more than 500 msec but rarely causes torsade de pointes.⁶² The antihistamine terfenadine, a potent I_{Kr} blocker that can cause torsade de pointes, nevertheless did not prolong action potentials in studies involving cardiac Purkinje fibers in dogs.⁶³ Thus, it is difficult to predict whether a particular drug will cause torsade de pointes in any single patient or in a population of patients (Fig. 3).

QT-interval-prolonging antiarrhythmic drugs represent one end of a spectrum of risk; torsade de pointes develops in more than 1 percent of patients who receive these agents (with the exception of amiodarone). This outcome can be readily predicted: in large groups of patients, these drugs have been shown to block I_{Kr} , increase the duration of action potentials, and prolong the average QT interval unambiguously (generally by more than 50 msec).

Terfenadine seems to represent the other end of the risk spectrum, given the nature of the evidence that it can induce torsade de pointes and that led to its withdrawal from the market.⁶⁴ The average prolongation of the QT interval in normal persons who are exposed to therapeutic doses of terfenadine is minimal — approximately 6 msec.³⁴ With larger doses, or in patients with heart failure (a setting of reduced repolarization reserve), the terfenadine-induced QT-interval prolongation is greater.³⁴

Terfenadine is a very potent I_{Kr} blocker but is nearly completely biotransformed by the CYP3A enzyme system before entering the systemic circulation. Its major metabolite, fexofenadine, is noncardioactive and is now marketed as Allegra. When CYP3A is inhibited (for example, by the simultaneous administration of erythromycin or ketoconazole⁶⁵) or overwhelmed (because of an overdose, for example⁶⁶), or when its activity is reduced by disease (such as cirrhosis^{67,68}), the concentration of unmetabolized terfenadine entering the systemic circulation increases markedly, resulting in a greater prolongation of the QT interval (Fig. 3).

Thus, the small change in the QT interval observed in normal volunteers exposed to usual doses of terfenadine can be interpreted in two ways. First, several million patients were exposed to terfenadine in the late 1980s and early 1990s with no recognized cases of torsade de pointes, so a mean increase of 6 msec might indicate that the drug confers next to no risk of torsade de pointes. On the other hand, this small increase in the QT interval




Figure 3. Effects of a Drug on Whole-Organ Function.

The effects of a drug on the function of an organ can be viewed as a cascade. The delivery of the drug to a molecular site of action is the first step. In each yellow area in the center of the figure, subsequent generic levels of action are shown on the left, with the specific example of drug-induced torsade de pointes on the right. Drug metabolites may also contribute to the clinical effects of the drug. At each level, physiological, genomic, or drug-specific or metabolite-specific properties may influence the drug effect that occurs; examples in the case of torsade de pointes associated with HERG blockade are shown on the right. A fundamental difficulty with toxic drug effects that occur at a low frequency is that an action at the level of a molecular target is an imperfect predictor of the effect on the whole organ.

might also suggest that certain patients might be at much higher risk in particular clinical circumstances. The experience with terfenadine suggests that a serious potential for toxic effects can arise with a potent I_{Kr} blocker that is eliminated by a single route of drug disposition, the activity of which depends on genetic factors, the presence or absence of disease, or the simultaneous administration of inhibitor compounds. In addition, patients with already reduced repolarization reserve (such as those with heart failure or subclinical congenital long-QT syndrome), who may not tolerate the insult or even a small increase in the QT interval, may be at increased risk for torsade de pointes.³⁴

WEIGHING RISKS AND BENEFITS

The decision by a physician to use a drug (or by a regulatory agency to approve one) is predicated on the assumption that the benefits of therapy, however defined, outweigh the risks. Arsenic trioxide presents an interesting example of this balance. Although this drug is known to provoke torsade de pointes,⁶⁹ it is also uniquely effective in an otherwise fatal disease, relapsed acute promyelocytic leukemia.⁷⁰ Therefore, until alternative therapy becomes available, arsenic trioxide remains a drug of first choice, despite its potential for causing arrhythmia. Similarly, bepridil may cause torsade de pointes but may provide antianginal activity in some patients whose symptoms are resistant to other drugs,⁷¹ and antiarrhythmic drugs conferring a high risk of torsade de pointes remain on the market because their benefits are believed to outweigh their risks, at least in some settings. On the other hand, a drug that causes even a very low incidence of torsade de pointes would be unacceptable if safer alternative forms of therapy were available or if the indication were not itself serious, however that term was defined.

New drugs present a special problem, because at the time approval by the Food and Drug Administration (FDA) is considered, clinical experience with each drug is limited, and many new agents may weakly antagonize I_{Kr} or produce a small but reproducible degree of QT-interval prolongation in thousands of patients. The decision ultimately rests on an estimate of the perceived risk relative to the expected benefits for patients and society. Estimates of benefit are specific to particular indications, but they may include an assessment of whether the specific disease entity itself is associated with very high

morbidity or mortality that the drug may be expected to reduce, as well as consideration of the efficacy and toxicity of other available therapies. These issues have been discussed extensively in FDA deliberations over several recent new drugs (e.g., moxifloxacin⁷² and ziprasidone⁷³). Both of these agents produce I_{Kr} blockade in vitro and have induced prolongation of the QT interval by 5 to 14 msec in clinical trials. In both cases, there was also a suggestion — unproved by formal clinical studies — of a clinical advantage over existing therapies in some settings.

DECISION MAKING AND DRUGS WITH QT-INTERVAL- PROLONGING POTENTIAL

Clinicians (often noncardiologists) are increasingly faced with both older and newly approved drugs with labeling that mentions the potential to prolong the QT interval and thus to cause torsade de pointes. Performing cardiovascular screening before prescribing such drugs seems unlikely to be cost effective; the package inserts for some, but not all, of the noncardiovascular drugs listed in Table 2 explicitly recommend obtaining a base-line electrocardiogram. However, a few simple aspects of the patient's history should alert a practitioner to a potentially increased risk.

Elderly women, persons with advanced heart disease, patients receiving other drugs that prolong the QT interval directly or indirectly (e.g., diuretics that cause hypokalemia), patients with a family history of sudden death, and patients with a complex medical regimen that includes drugs with the potential to inhibit important drug-elimination mechanisms are all at increased risk. Certain drugs frequently inhibit drug elimination (through a variety of mechanisms) and thus should be a cause for special concern; examples include erythromycin, clarithromycin, ketoconazole, itraconazole, amiodarone, quinidine, and many antidepressants and antiretroviral agents.⁷⁴

If therapy with a drug that has QT-interval-prolonging potential is started, patients should be warned to report promptly any symptoms such as new palpitations and near-syncope or syncope (even without palpitations), as well as intercurrent conditions or therapies that can cause hypokalemia (e.g., gastroenteritis or the addition of a diuretic to the patient's regimen). Routine electrocardiographic examination during treatment to detect asymp-

tomatic prolongation of the QT interval to more than 500 msec or abnormal postectopic QT intervals (Fig. 1) may be considered in such high-risk situations, although whether these precautions can reduce risk is unknown.

If any rare but serious adverse drug reaction occurs often enough, and if alternative therapies are available, the offending drug may be withdrawn from the market, even if the mechanisms underlying the adverse effect are not understood. The current understanding of the mechanisms that cause torsade de pointes changes this situation: a drug may now be implicated as a potential cause of the adverse effect (at some unknown frequency) even in the absence of any cases. The recognition of these mechanisms highlights important issues in the risk-benefit analyses performed daily by the medical community. Clinical pharmacokinetic principles indicate that drugs that interact with a protein that mediates serious toxicity (such as the HERG protein) and that are eliminated by a single route of drug disposition may present an especially serious problem. Genetic variants, disease, or the simultaneous administration of inhibitor compounds are most likely to alter the drug concentrations, and hence the level of risk, in this situation (Fig. 3).

Although it may be difficult, it is important to educate health care providers and to develop pharmacy systems that detect the simultaneous prescribing of drugs with the potential for serious adverse interactions. However, multiple attempts by regulatory agencies and drug companies to limit the administration of dangerous combinations, such as cisapride and erythromycin, have been only transiently successful.⁷⁵⁻⁷⁷ Prescribers should recognize that most drugs have multiple, and often unanticipated, actions. In addition, even drugs that are designed to interact with a single molecular target act in a complex biologic milieu. Unusual drug reac-

tions may arise as a result of multiple factors, including changes in physiology conferred by the disease being treated, genetics, or environment (e.g., reduced repolarization reserve). Common gene polymorphisms may modulate patients' susceptibility to adverse drug reactions. Finally, evaluation of the risk of toxic drug effects may include the assessment of a drug's effects on physiologically rational surrogate markers (such as the QT interval), but it is rare that there is a one-to-one correspondence between a surrogate for a toxic effect and the effect itself.

BROADER IMPLICATIONS

Rare, poorly understood side effects occur with many highly effective drugs, and the withdrawal of these medications from the market would probably harm more patients than it would help. Our partial understanding of the mechanisms underlying torsade de pointes is a two-edged sword. On the one hand, drug safety has been improved: we are unlikely to see more new drugs that unexpectedly result in a high risk of torsade de pointes after they have reached the market.⁷⁸ On the other hand, as the molecular markers of risk for this and other unusual actions of drugs are elucidated, there is a great risk of paralyzing the drug-development process in what is probably a fruitless effort to develop drugs that are entirely devoid of adverse effects. Ultimately, the cost to society of marketing new drugs associated with at most an extremely small incidence of the serious adverse effects that are now crudely predictable on the basis of preclinical experience must be weighed against the overall benefits that such new therapies may confer.

Supported in part by grants (HL46681, HL49989, and HL65962) from the Public Health Service.

REFERENCES

1. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. *JAMA* 2002;287:2215-20.
2. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications: report on a policy conference of the European Society of Cardiology. *Eur Heart J* 2000;21:1216-31.
3. Anderson ME, Al Khatib SM, Roden DM, Califf RM. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. *Am Heart J* 2002;144:769-81.
4. Selzer A, Wray HW. Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrhythmias. *Circulation* 1964;30:17-26.
5. Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. *Arch Mal Coeur* 1966;59:263-72.
6. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval, and sudden death. *Am Heart J* 1957;54:59-68.
7. Romano C, Gemme G, Pongiglione R. Aritmie cardiache rare in dell'eta pediatrica. *Clin Pediatr* 1963;45:656-83.
8. Ward OC. A new familial cardiac syndrome in children. *J Ir Med Assoc* 1964;54:103-6.
9. Viskin S, Fish R, Zeltser D, et al. Arrhythmias in the congenital long QT syndrome: how often is torsade de pointes pause dependent? *Heart* 2000;83:661-6.

10. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. *JAMA* 1993;270:2590-7.
11. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsades de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. *J Am Coll Cardiol* 1983;2:806-17.
12. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. *Am Heart J* 1986;111:1088-93.
13. Choy AMJ, Darbar D, Dell'Orto S, Roden DM. Exaggerated QT prolongation and cardioversion of atrial fibrillation. *J Am Coll Cardiol* 1999;34:396-401.
14. Nowinski K, Gadler F, Jensen-Urstad M, Bergfeldt L. Transient proarrhythmic state following atrioventricular junction radiofrequency ablation: pathophysiologic mechanisms and recommendations for management. *Am J Med* 2002;113:596-602.
15. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. *N Engl J Med* 1999;341:857-65.
16. Houltz B, Darpo B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. *Pacing Clin Electrophysiol* 1998;21:1044-57.
17. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. *Cardiovasc Res* 1993;27:2186-93.
18. Donger C, Denjoy I, Berthet M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. *Circulation* 1997;96:2778-81.
19. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. *J Cardiovasc Electrophysiol* 2000;11:691-6.
20. Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. *Proc Natl Acad Sci U S A* 2000;97:10613-8.
21. Wei J, Yang IC-H, Tapper AR, et al. *KCNK1* polymorphism confers risk of drug-induced long QT syndrome by altering kinetic properties of I_{Ks} potassium channels. *Circulation* 1999;100:Suppl I:I-495. abstract.
22. Splawski I, Timothy KW, Tateyama M, et al. Variant of *SCN5A* sodium channel implicated in risk of cardiac arrhythmia. *Science* 2002;297:1333-6.
23. Yang T, Roden DM. Extracellular potassium modulation of drug block of I_{Kr} : implications for torsades de pointes and reverse use-dependence. *Circulation* 1996;93:407-11.
24. Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. *Circulation* 1998;97:2237-44.
25. Wu Y, Anderson ME. Reduced repolarization reserve in ventricular myocytes from female mice. *Cardiovasc Res* 2002;53:763-9.
26. Pham TV, Sosunov EA, Gainullin RZ, Danilo P Jr, Rosen MR. Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by I(K)-blocking drugs. *Circulation* 2001;103:2207-12.
27. Pham TV, Sosunov EA, Anyukhovsky EP, Danilo P Jr, Rosen MR. Testosterone diminishes the proarrhythmic effects of dofetilide in normal female rabbits. *Circulation* 2002;106:2132-6.
28. Drici MD, Burklow TR, Haridasse V, Glazer RI, Wossley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. *Circulation* 1996;94:1471-4.
29. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. *Pacing Clin Electrophysiol* 1998;21:1029-34.
30. Gbadebo TD, Trimble RW, Khoo MS, Temple J, Roden DM, Anderson ME. Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. *Circulation* 2002;105:770-4.
31. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. *J Am Coll Cardiol* 2000;35:778-86.
32. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. *Circulation* 1996;94:1613-21.
33. Velebit V, Podrid P, Lown B, Cohen BH, Graboyes TB. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. *Circulation* 1982;65:886-94.
34. Pratt CM, Ruberg S, Morganroth J, et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. *Am Heart J* 1996;131:472-80.
35. Khongphattananayothin A, Lane J, Thomas D, Yen L, Chang D, Bubolz B. Effects of cisapride on QT interval in children. *J Pediatr* 1998;133:51-6.
36. Lee WM. Drug-induced hepatotoxicity. *N Engl J Med* 2003;349:474-85.
37. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. *JAMA* 1993;269:1532-6.
38. Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. *BMJ* 2002;325:1070.
39. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. *N Engl J Med* 2003;348:1866-74.
40. Vila JA, Gang Y, Rodriguez Presedo JM, Fernandez-Delgado M, Barro S, Malik M. A new approach for TU complex characterization. *IEEE Trans Biomed Eng* 2000;47:764-72.
41. Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. *Heart* 2002;87:220-8.
42. Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: relationship to potassium and cycle length. *Circ Res* 1985;56:857-67.
43. Brachmann J, Scherlag BJ, Rosenshtraukh LV, Lazzara R. Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. *Circulation* 1983;68:846-56.
44. Yan GX, Shimizu W, Antzelevitch C. Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. *Circulation* 1998;98:1921-7.
45. Akar FG, Yan GX, Antzelevitch C, Rosenbaum DS. Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. *Circulation* 2002;105:1247-53.
46. Sicouri S, Antzelevitch C. Drug-induced afterdepolarizations and triggered activity occur in a discrete subpopulation of ventricular muscle cells (M cells) in the canine heart: quinidine and digitalis. *J Cardiovasc Electrophysiol* 1993;4:48-58.
47. el-Sherif N, Caref EB, Yin H, Restivo M. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome: tridimensional mapping of activation and recovery patterns. *Circ Res* 1996;79:474-92.
48. El-Sherif N, Caref EB, Chinushi M, Restivo M. Mechanism of arrhythmogenicity of the short-long cardiac sequence that precedes ventricular tachyarrhythmias in the long QT syndrome. *J Am Coll Cardiol* 1999;33:1415-23.
49. Burashnikov A, Antzelevitch C. Block of I(Ks) does not induce early afterdepolarization activity but promotes beta-adrenergic agonist-induced delayed afterdepolarization activity. *J Cardiovasc Electrophysiol* 2000;11:458-65.
50. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: *HERG* mutations cause long QT syndrome. *Cell* 1995;80:795-803.
51. Wang Q, Shen J, Splawski I, et al. *SCN5A* mutations associated with an inherited cardiac arrhythmia, long QT syndrome. *Cell* 1995;80:805-11.

52. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: *KVLQT1* mutations cause cardiac arrhythmias. *Nat Genet* 1996;12:17-23.
53. Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT. Mutations in the *hminK* gene cause long QT syndrome and suppress I_{Ks} function. *Nat Genet* 1997;17:338-40.
54. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. *Cell* 2001;104:569-80.
55. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. *Nature* 2003;421:634-9.
56. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: *HERG* encodes the I_{Kr} potassium channel. *Cell* 1995;81:299-307.
57. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. *Circulation* 1999;99:529-33.
58. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. *Circulation* 2002;105:1943-8.
59. Zhang S, Zhou Z, Gong Q, Makielski JC, January CT. Mechanism of block and identification of the verapamil binding domain to *HERG* potassium channels. *Circ Res* 1999;84:989-98.
60. Yang T, Snyders D, Roden DM. Drug block of $I_{(kr)}$: model systems and relevance to human arrhythmias. *J Cardiovasc Pharmacol* 2001;38:737-44.
61. Nattel S, Quantz MA. Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms. *Cardiovasc Res* 1988;22:808-17.
62. Lazzara R. Amiodarone and torsades de pointes. *Ann Intern Med* 1989;111:549-51.
63. Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BE. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. *J Cardiovasc Pharmacol* 2001;37:607-18.
64. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. *JAMA* 1990;264:2788-90.
65. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. *JAMA* 1993;269:1513-8. [Erratum, *JAMA* 1993;269:2088.]
66. Davies AJ, Harindra V, McEwan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. *BMJ* 1989;298:325.
67. Venturini E, Borghi E, Maurini V, Vecce R, Carnicelli A. Allungamento dell'intervallo Q-T ed aritmie ventricolari ipercinetiche probabilmente indotte dall'uso di terfenadine in paziente con cirrosi epatica. *Recenti Prog Med* 1992;83:21-2.
68. Kamisako T, Adachi Y, Nakagawa H, Yamamoto T. Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma. *Intern Med* 1995;34:92-5.
69. Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. *Ann Intern Med* 2001;133:881-5.
70. Huan SY, Yang CH, Chen YC. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a useful salvage therapy. *Leuk Lymphoma* 2000;38:283-93.
71. Singh BN. Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. *Am J Cardiol* 1991;68:306-12.
72. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research. Anti-Infective Drugs Advisory Committee, 67th meeting, Thursday, October 21, 1999 (transcript). (Accessed February 9, 2004, at <http://www.fda.gov/ohrms/dockets/ac/99/transcript/3558t2a.pdf>.)
73. Food and Drug Administration, Center for Drug Evaluation and Research. Psychopharmacologic Drugs Advisory Committee proceedings, Wednesday, July 19, 2000 (transcript). (Accessed February 9, 2004, at <http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3619t1a.pdf>.)
74. Abernethy DR, Flockhart DA. Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. *Circulation* 2000;101:1749-53.
75. Burkhart GA, Sevka MJ, Temple R, Honig PK. Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. *Clin Pharmacol Ther* 1997;61:93-6.
76. Cavuto NJ, Woosley RL, Sale M. Pharmacies and prevention of potentially fatal drug interactions. *JAMA* 1996;275:1086-7.
77. Woosley RL. Drug labeling revisions — guaranteed to fail? *JAMA* 2000;284:3047-9.
78. Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. *JAMA* 2002;287:2273-5.

Copyright © 2004 Massachusetts Medical Society.

PERSONAL ARCHIVES IN THE JOURNAL ONLINE

Individual subscribers can store articles and searches using a feature on the *Journal's* Web site (www.nejm.org) called "Personal Archive." Each article and search result links to this feature. Users can create personal folders and move articles into them for convenient retrieval later.